XM non fornisce servizi ai residenti degli Stati Uniti d'America.

XM non fornisce servizi ai residenti degli Stati Uniti d'America.
W
W

Walgreens

News

Reuters - 3 giorni fa

Commercial REIT FrontView valued at $488 mln as shares drop in NYSE debut

UPDATE 3-Commercial REIT FrontView valued at $488 mln as shares drop in NYSE debut Adds analyst comment in paragraph 6 By Vedant Vinayak Vichare Oct 2 (Reuters) - Shares of FrontView REIT FVR.N fell 3.9% in their debut on the New York Stock Exchange on Wednesday, valuing the commercial real estate investment trust at $487.9 million. The Dallas, Texas-based company's shares opened at $18.25, below the initial public offering price of $19 apiece.
A
S
W
Reuters - 3 giorni fa

CVS surgery would provide little if any relief

RPT-BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W
Reuters - 3 giorni fa

CVS surgery would provide little if any relief

RPT-BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W
Reuters - 4 giorni fa

CVS surgery would provide little if any relief

BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W
Reuters - 5 giorni fa

Estee Lauder to see green shoots in China demand after stimulus, Piper Sandler says

BUZZ-Estee Lauder to see green shoots in China demand after stimulus, Piper Sandler says Updates ** Shares of cosmetics maker Estee Lauder EL.N rise as much as 3.6 % a t $103.4 4 after brokerage Piper Sandler raises PT to $122 from $114 ** Sees possible near-term positive effects of stimulus measures in China o n EL * * Brokerage conveys confidence in EL's FY25 forecast as co expects a decline in China sales in H1 * * EL's stock hits its highest since July 12 ** Brokerage warns of minor pressure
W
E
Reuters - 5 giorni fa

Estee Lauder to see green shoots in China demand after stimulus, Piper Sandler says

BUZZ-Estee Lauder to see green shoots in China demand after stimulus, Piper Sandler says ** Shares of cosmetics maker Estee Lauder EL.N rise 1% to $100.89 premarket after brokerage Piper Sandler raises PT to $122 from $114 ** Sees possible near-term positive effects of stimulus measures in China to EL, conveys confidence in its FY25 forecast as co expects a decline in China sales in H1 ** Brokerage warns of minor pressure on Coty's COTY.N mass cosmetics demand, maintains PT at $13 ** Says recent
W
E
Reuters - 1 settimana fa

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
A
C
E
L
R
S
W
W
U
U
D
C
L
Reuters - 1 settimana fa

California says Exxon's recycling claims created a 'public nuisance.' What does that mean?

EXPLAINER-California says Exxon's recycling claims created a 'public nuisance.' What does that mean? By Brendan Pierson Sept 25 (Reuters) - California's lawsuit on Monday accusing Exxon XOM.N of fueling global plastic waste pollution by misleading the public about the limitations of recycling is the latest in a line of recent cases based on a centuries-old legal theory known as public nuisance.
N
P
W
C
Reuters - 3 settimane fa

Baltimore to take drug distributors to trial over opioids

UPDATE 1-Baltimore to take drug distributors to trial over opioids Adds comment from Cencora in paragraph 4 By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M
Reuters - 3 settimane fa

Baltimore to take drug distributors to trial over opioids

CORRECTED-Baltimore to take drug distributors to trial over opioids Corrects headline and lead, adds paragraphs 4-5 to state that J&J settled before trial By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M
Reuters - 3 settimane fa

Walgreens paying $106.8 million to settle US prescription billing fraud charges

UPDATE 3-Walgreens paying $106.8 million to settle US prescription billing fraud charges Adds Justice Department comment, share price, paragraphs 4, 13 By Jonathan Stempel Sept 13 (Reuters) - Walgreens Boots Alliance WBA.O agreed to pay $106.8 million to settle charges it fraudulently billed the U.S. government for prescriptions that were never dispensed, the Department of Justice said on Friday.
W
Reuters - 3 settimane fa

CORRECTED Walgreens paying $106.8 million to settle US prescription billing fraud charges

CORRECTED (OFFICIAL)-UPDATE 2-Walgreens paying $106.8 million to settle US prescription billing fraud charges Corrects paragraph 3 to remove discussion of Walgreens reselling prescriptions and effectively being paid twice, after U.S. Department of Justice corrects press release to remove that accusation By Jonathan Stempel Sept 13 (Reuters) - Walgreens Boots Alliance WBA.O agreed to pay $106.8 million to settle charges it fraudulently billed the U.S.
W
Reuters - 3 settimane fa

Walgreens agrees to pay $106.8 mln to settle US charges over prescription billing

Walgreens agrees to pay $106.8 mln to settle US charges over prescription billing Sept 13 (Reuters) - Walgreens Boots Alliance WBA.O agreed to pay $106.8 million to settle charges it billed the U.S. government for prescriptions that were never dispensed, the Department of Justice said on Friday. The Justice Department said that from 2009 to 2020, Walgreens submitted false claims for payment to Medicare, Medicaid and other federal health care programs for prescriptions it processed but which were
W
Reuters - 3 settimane fa

UK's Boots names Anthony Hemmerdinger as new boss

UK's Boots names Anthony Hemmerdinger as new boss LONDON, Sept 12 (Reuters) - British health and beauty retailer Boots has promoted Anthony Hemmerdinger to the managing director role, succeeding Seb James on Nov. 4, it said on Thursday. Boots UK, owned by U.S. listed Walgreens Boots Alliance WBA.O , is one of Britain's biggest retailers, trading from about 1,900 stores and employing 52,000. Hemmerdinger, a former Asda supermarket executive, has been Boots UK's retail and operations director sinc
W
Reuters - 4 settimane fa

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

UPDATE 1-Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial Adds comment from J&J in paragraph 6 By Brendan Pierson Sept 10 (Reuters) - Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
T
W
M
Reuters - 4 settimane fa

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial By Brendan Pierson Sept 10 (Reuters) - Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
T
W
M
Reuters - 4 settimane fa

Jefferies cuts PT on drug distributor McKesson, raises PT on Cardinal

BUZZ-Jefferies cuts PT on drug distributor McKesson, raises PT on Cardinal ** Brokerage Jefferies cuts PT on drug distributor McKesson MCK.N to $607 from $630, while raising PT on peer Cardinal Health CAH.N to $110 from $105 ** Says despite MCK forecasting Q2 below estimates, co's reiteration of full-year forecast gives "some level of confidence" *
W
M
Reuters - 4 settimane fa

From Boeing to FedEx, US labor unions flex muscle

FACTBOX-From Boeing to FedEx, US labor unions flex muscle Adds details throughout By Mrinalika Roy Oct 1 (Reuters) - The first large-scale strike by dockworkers on the U.S. East and Gulf coast in nearly 50 years, blocking everything from food to automobile shipments, has highlighted again the increasing mobilization by unions in the country since last year.
B
J
S
V
W
U
A
U
W
Reuters - 4 settimane fa

Walgreens hit with lawsuit claiming generic cold medicine has cancer-causing chemical

Walgreens hit with lawsuit claiming generic cold medicine has cancer-causing chemical By Diana Novak Jones Sept 4 (Reuters) - Walgreens is facing a proposed class action lawsuit brought on Wednesday by customers who say they weren’t warned that the pharmacy chain’s generic version of cold medicine Mucinex contains a cancer-causing chemical. The lawsuit, filed in Chicago federal court, claims Walgreens did not label the products or otherwise warn customers that they contained benzene, a known
W
Reuters - 1 mese fa

U.S. STOCKS Dyne Therapeutics, Maxeon Solar, chip stocks

BUZZ-U.S. STOCKS ON THE MOVE-Dyne Therapeutics, Maxeon Solar, chip stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell over 1% on Tuesday as investors assessed subdued factory activity data ahead of a slew of labor market reports due through the week that could influence the extent of monetary policy easing by the Federal Reserve.
B
C
C
G
I
M
N
N
R
T
W
A
U
R
U
U
U
S
T
X
I
M
M
R

Condizioni

Asset popolari

Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.

Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.

Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.

Avvertenza sul rischio: Il tuo capitale è a rischio. I prodotti con leva finanziaria possono non essere adatti a tutti. Ti chiediamo di consultare attentamente la nostra Informativa sul rischio.